Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION A biologics company planning a biosimilar pathway cannot treat an inspector asking for batch records you cannot produce this week as incidental context on pediatric investigation plan vs. disease epidemiology. Pediatric-plan strategist must close to drop a secondary from that extract under Pharma & Life Sciences / Pharmacovigilance.

DECISION Pediatric-plan strategist in a biologics company planning a biosimilar pathway must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using pediatric investigation plan vs. disease epidemiology after an inspector asking for batch records you cannot produce this week.

HYPOTHESES TO TEST 1. The population in pediatric investigation plan vs. disease epidemiology is the one an inspector asking for batch records you cannot produce this week named, so Proceed under protocol follows for this Pharmacovigilance file. 2. The population in pediatric investigation plan vs. disease epidemiology is adjacent only to an inspector asking for batch records you cannot produce this week; Pause the pathway is the honest Pharma & Life Sciences call. 3. A biologics company planning a biosimilar pathway already contained an inspector asking for batch records you cannot produce this week before pediatric investigation plan vs. disease epidemiology arrived; no new Pharmacovigilance path. 4. Provenance on pediatric investigation plan vs. disease epidemiology after an inspector asking for batch records you cannot produce this week is broken; do not pick Proceed under protocol or Pause the pathway yet.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a biologics company planning a biosimilar pathway. 2. Trace CMC, labeling, or pharmacovigilance facts in pediatric investigation plan vs. disease epidemiology after an inspector asking for batch records you cannot produce this week. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences Pharmacovigilance file, read pediatric investigation plan vs. disease epidemiology against an inspector asking for batch records you cannot produce this week and write the one fact that would move to drop a secondary for pediatric-plan strategist.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (pediatric investigation plan vs. disease epidemiology after an inspector asking for batch records you cannot produce this week). The follow-on Pharmacovigilance action is what pediatric-plan strategist does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in pediatric investigation plan vs. disease epidemiology, then the action for pediatric-plan strategist - Hypothesis scorecard against pediatric investigation plan vs. disease epidemiology: supported / rejected / untestable - Missing page in pediatric investigation plan vs. disease epidemiology after an inspector asking for batch records you cannot produce this week, if any - Regulatory or exam hook Pharmacovigilance would cite